Localisation of malignant glioma by a radiolabelled human monoclonal antibody.
Open Access
- 1 May 1983
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 46 (5) , 388-392
- https://doi.org/10.1136/jnnp.46.5.388
Abstract
Human monoclonal antibodies were produced by fusing intratumoral lymphocytes from patients with malignant gliomas with a human myeloma line. One antibody was selected for further study after screening for binding activity to glioma cell lines. The patient from whom it was derived developed recurrent glioma. 1 mg of antibody was purified, radiolabelled with 131I, and administered intravenously. The distribution of antibody was determined in the blood, CSF and tumour cyst fluid and compared with that of a control human monoclonal immunoglobulin. Antibody localisation in the tumour was observed and confirmed by external scintiscanning.This publication has 4 references indexed in Scilit:
- PHASE-I CLINICAL TRIAL OF MONOCLONAL ANTIBODY IN TREATMENT OF GASTROINTESTINAL TUMOURSThe Lancet, 1982
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982
- HUMAN HYBRIDOMAS FROM MALIGNANT GLIOMASThe Lancet, 1982
- A procedure for the fusion of cells in suspension by means of polyethylene glycolSomatic Cell and Molecular Genetics, 1977